Beyondspring Stock

Beyondspring FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Beyondspring (BYSI) as of Sep 4, 2026 is 149.84 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 78.83 % — a change of 90.09% (higher).

FCF Conversion

149.84 %

YoY

90.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Beyondspring is 2026 149.84 % . FCF Conversion Rate (FCF/EBITDA) of Beyondspring was 2025 78.83 % . It decreases by 90.09% higher compared to the previous year.

The Beyondspring FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
31.46 USD
Jan 1, 2018
73.20 USD
Jan 1, 2019
126.47 USD
Jan 1, 2020
71.83 USD
Jan 1, 2021
78.04 USD
Jan 1, 2022
84.69 USD
Jan 1, 2023
78.83 USD
Jan 1, 2024
149.84 USD
The Beyondspring FCF Conversion history
YEARFCF ConversionYoY
149.84 %+90.09%
78.83 %-6.93%
84.69 %+8.52%
78.04 %+8.65%
71.83 %-43.20%
126.47 %+72.78%
73.20 %+132.64%
31.46 %-72.54%
114.59 %+38.16%
82.94 %+118.05%
38.04 %
Access this data via the Eulerpool API

Beyondspring Stock analysis

What does Beyondspring do? Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes. Beyondspring is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beyondspring stock

FCF Conversion Rate (FCF/EBITDA) of Beyondspring is 149.84 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Beyondspring changed from 78.83 % to 149.84 %, representing a 90.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Beyondspring since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Beyondspring with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Beyondspring

All Key Metrics — Beyondspring